ÂÜÀòÂÒÂ×

Sushmita M. Chanda is currently the EVP of Translational Safety Sciences at Aligos Therapeutics. Sushmita has over 18 years of experience in the pharmaceutical industry.

Sushmita started their career at Sugen Inc as a Toxicologist in 1998. Sushmita then moved to Roche Palo Alto in 2000 as the Sr. Director, Head Non Clinical Safety. In 2010, they joined Alios BioPharma as VP of Preclinical Development.

Sushmita has played a vital role in the development and approval of many drugs, including small molecules and biologics. Sushmita is an expert in the field of translational safety and has helped Aligos Therapeutics become a leader in this area.

Sushmita M. Chanda completed their postdoctoral training in the field of toxicology at the University of North Carolina at Chapel Hill. Sushmita then went on to earn their Ph.D. in toxicology and pharmacology from the University of Louisiana Monroe. Sushmita is also certified by the American Board of Toxicology, Inc. as a Diplomate of the American Board of Toxicology.

They are on a team with John Fry - EVP, Clinical Development, David B. Smith - EVP, Head of Chemical Operations, and Lesley Ann Calhoun - EVP, CFO. Their manager is Lawrence M. Blatt, Chief Executive Officer and Director.